We report five South African families of northern European descent (pedigrees 161, 162, 163, 164, and 166) in whom Romano-Ward long QT syndrome (LQT) segregates. The disease mapped to a group oflinked markers on chromosome llp15.5, with maximum combined two point lod scores, all generated at 0=0, of 15-43 for the DllS922, 10'51 for the D11S1318, and 14*29 for the tyrosine hydroxylase (TH) loci. Recent studies have shown that LQT is caused by an Ala212Val mutation in a potassium channel gene (KVLQT1) in pedigrees 161 to 164. We report that the same mutation is responsible for the disease in pedigree 166. Haplotype construction showed that all the families shared a common haplotype, suggesting a founder gene effect. DNA based identification of gene carriers allowed assessment of the clinical spectrum of LQT. The QTc interval was significantly shorter in both carriers and non-carriers in pedigree 161 (0.48 s and 0 39 s, respectively) than the same two groups in pedigree 161 (0.52 s and 0-42 s, respectively). The spectrum of clinical symptoms appeared more severe in pedigree 162. The possible influence of modulating genetic factors, such as HLA status and sex of family members, on the expression of an LQT founder gene is discussed.
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Familial long QT syndrome (LQT) is characterised by recurrent syncope and early sudden death resulting from cardiac arrhythmias, with affected subjects frequently exhibiting prolongation of the QT interval on electrocardiograms.'2 Cardiac events are often associated with periods of heightened autonomic tone, such as exercise, anxiety, or excitement. 3 The first evidence of genetic heterogeneity, which has subsequently become a feature of this disease, was the early recognition of two familial forms of LQT. The more commonly occurring Romano-Ward syndrome is distinguished by an autosomal dominant mode of inheritance and normal hearing,45 in contrast to the autosomal recessive inheritance pattern and deafness associated with Jervell-LangeNielsen syndrome. 6 The existence of familial forms of LQT has provided the opportunity of 
Results

ASCERTAINMENT OF PHENOTYPE
The five families identified, pedigrees 161 to 164 and pedigree 166 (fig 1) , showed an autosomal dominant mode of inheritance, normal hearing, and characteristic features associated with the Romano-Ward form of LQT. The spectrum of clinical presentation is discussed below.
Electrocardiographic data were available for 78 family members, and blood samples for genotypic analysis were available for 100 people.
MUTATION DETECTION AND HAPLOTYPE CONSTRUCTION
,wc. ,.
Forty eight of the total of 100 family members , ' 9' of the five pedigrees subjected to genotypic analysis at KVLQT1 carried the Ala212Val mutation (fig 1) . These results incorporated data generated for some family members of pedigrees 161 to 164 genotyped in a previous study14 and subjects newly entered into the present study, as well as new information for pedigree 166.
The highest combined lod scores generated between LQT and marker loci were at D11S922 (Zmax group.bmj.com on July 7, 2017 -Published by http://jmg.bmj.com/ Downloaded from people had an equivocal electrocardiogram, that is, <0 45 s (III7 and III 11). Mutation analysis indicated that three of the five equivocal subjects in pedigree 161 were gene carriers (II-4, III-7, and III11). However, in pedigree 162, six of the seven equivocal people were non-carriers (III 1, III-20, III-25, IV-4, IV-7, and IV-8), while DNA of the seventh person (III24) was not available for genotyping. Consequently, the total number of gene carriers and non-carriers assessed in comparative clinical studies was 48 and 30 respectively (27 from the direct line of descent and three spouses). Of the gene carriers, 21 were male (45%) and 26 were female (55%), the monozygotic twins III2 and III4 in pedigree 162 being counted as a single genetic event.
Syncopal episodes were suffered by 38/48 (79%) of the gene carriers in the five pedigrees. When making comparisons of clinical features in pedigrees 161 and 162 only, it was evident that the majority of the seven asymptomatic carriers in these two pedigrees were members of pedigree 161 (six out of seven people). None ofthe non-carrier family members had a history ofsyncope. The age ofthe first reported episode of symptoms in carriers also showed a difference between the two pedigrees, with a range of from 3 to 42 years (mean 11 years) in pedigree 161 and from 2 to 12 years (mean 6 years) in pedigree 162. The average number of syncopal episodes per person was lower in pedigree 161 (6-75 episodes) than in pedigree 162 (nine episodes).
When making a comparative analysis of the clinical spectrum in the two larger pedigrees, it was apparent that the range and mean of the QTc interval was shorter in pedigree 161 than in pedigree 162 in both carriers and non-carriers (fig 2) . In pedigree 161, QTc ranged from 0-44 s to 0-53 s (mean 0-48 s) in carriers and from 0-35 s to 0 44 s (mean 0-39 s) in noncarriers. In pedigree 162, QTc ranged from 0 45 s to 0 59 s (mean 0-52 s) in carriers and from 0-37 s to 045 s (mean 042 s) in noncarriers. An analysis of variance showed these differences to be statistically significant, when comparing the QTc of carriers (p = 0003) or non-carriers (p = 0-0 143) in the two pedigrees. This may mean that the "normal" QTc variation existing within families may play an additional contributory role in the length of the pathological QTc interval.
The numbers of gene carriers in pedigrees 163, 164, and 165 were not large enough for statistical comparisons of QTc interval, but members of pedigree 164 appeared to be most severely affected, with the QTc ranging from 0 49 s to 0 70 s (mean 0-56 s), accompanied by frequent episodes of syncope and convulsions. The QTc in three non-carriers from the direct line of descent in pedigree 164 was 0-41 s ( fig  1) .
All episodes of syncope in the five pedigrees were preceded by activity or excitement, with a notably high occurrence (53%) associated with swimming or participation in water related exercise. Ten patients reported syncopal attacks after emotional upset. In 11 patients the loss Seven of the 10 asymptomatic carriers were receiving no treatment, while the remaining three were given 1 blockade. Seven of the symptomatic carriers were untreated and, of these, II 9, II-15, (pedigree 161) II-2, II5 (pedigree 162), and Ii1 (pedigree 166), aged 68, 62, 71, 74, and 68 years respectively, had been symptom free for 38 years or more. III 1 (pedigree 161), aged 16 years, had suffered only one previous attack at the age of 10 years and showed an equivocal ECG. II-2 (pedigree 164), with a QTc of 0 70 s, declined treatment and had not suffered syncope or convulsions for the past two years. Of the remaining 31 symptomatic carriers, 23 were on P blockade alone, three had undergone left sympathetic ganglionectomy, and five were on 1 blockade therapy as well as having undergone ganglionectomy. All patients receiving treatment were free of further syncopal episodes, with the exception of IV 13 (pedigree 162), III-7 (pedigree 164), and II-4 (pedigree 166). The first patient seemed resistant to surgery and the subsequent reintroduction of P blockade and had suffered a further five episodes of syncope despite treatment. Both his sibs (IV-11 and IV-12), as well as his mother (III 14), were severely affected and had undergone surgical intervention, although in their cases treatment had proved effective. The other two patients had not undergone surgery, the 13 year old III-7 continued to suffer syncopal episodes, while II-4 had been symptom free for eight years.
Discussion
In the five pedigrees described, LQT was caused by an Alal21Val mutation in KVLQT1 on chromosome lip15.5. A common haplotype at markers linked to the mutant allele indicated descent from a common ancestor. Evidence to support the premise that this was the disease causing mutation included identification of an Ala212Val substitution in an unrelated family (KI807) of Italian origin and its absence in 200 unaffected controls reported in a previous study. '4 In addition, an Ala212Glu mutation in the same KVLQT1 codon has been implicated as a cause of LQT in two families. ' 4 Three of the nine clinically equivocal subjects, namely II4, III 7, and III-11 (pedigree 161), had inherited the mutant allele. Consequently, in these at risk family members, treatment combined with the avoidance of precipitating factors, would be advised. The remaining clinically equivocal family members could be reassured that they were not gene carriers and be spared unnecessary treatment.
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